loxapine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
psychoactive	1613	1977-10-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: loxapine loxapin oxilapine loxapine succinate cloxazepine loxitane adasuve loxapine hydrochloride loxapine HCl loxipine maleate	An antipsychotic agent used in SCHIZOPHRENIA. Molecular weight: 327.81 Formula: C18H18ClN3O CLOGP: 3.68 LIPINSKI: 0 HAC: 4 HDO: 0 TPSA: 28.07 ALOGS: -3.50 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

loxapine
loxapin
oxilapine
loxapine succinate
cloxazepine
loxitane
adasuve
loxapine hydrochloride
loxapine HCl
loxipine maleate

An antipsychotic agent used in SCHIZOPHRENIA.

Molecular weight: 327.81
Formula: C18H18ClN3O
CLOGP: 3.68
LIPINSKI: 0
HAC: 4
HDO: 0
TPSA: 28.07
ALOGS: -3.50
ROTB: 0

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
9.10	mg	Inhal.powder
0.10	g	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	30 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Feb. 25, 1975	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	355.14	34.87	139	3569	56740	50544676
Poisoning deliberate	350.56	34.87	87	3621	7825	50593591
Neuroleptic malignant syndrome	220.96	34.87	65	3643	11065	50590351
Extrapyramidal disorder	150.13	34.87	49	3659	11721	50589695
Hepatocellular injury	146.01	34.87	59	3649	25888	50575528
Cholestasis	123.36	34.87	52	3656	25349	50576067
Oculogyric crisis	111.94	34.87	25	3683	1412	50600004
Somnolence	110.60	34.87	91	3617	154894	50446522
Intestinal obstruction	92.55	34.87	43	3665	26340	50575076
Toxicity to various agents	84.23	34.87	90	3618	212409	50389007
Pneumonia aspiration	71.49	34.87	38	3670	30966	50570450
Benzodiazepine drug level increased	69.33	34.87	12	3696	175	50601241
Altered state of consciousness	65.49	34.87	32	3676	21878	50579538
Galactorrhoea	61.95	34.87	19	3689	3704	50597712
Catatonia	61.88	34.87	19	3689	3717	50597699
Intentional overdose	60.34	34.87	44	3664	62460	50538956
Hypothermia	59.61	34.87	25	3683	11991	50589425
Hyperprolactinaemia	59.52	34.87	18	3690	3347	50598069
Brain death	58.44	34.87	17	3691	2766	50598650
Faecaloma	57.21	34.87	21	3687	7087	50594329
Tachycardia	55.64	34.87	51	3657	99712	50501704
Antipsychotic drug level above therapeutic	49.77	34.87	12	3696	947	50600469
Hypotension	48.52	34.87	72	3636	235397	50366019
Hyperthermia	48.44	34.87	19	3689	7677	50593739
Miosis	48.42	34.87	18	3690	6292	50595124
Rhabdomyolysis	48.26	34.87	32	3676	38995	50562421
Intestinal pseudo-obstruction	47.30	34.87	11	3697	743	50600673
Dystonia	46.70	34.87	21	3687	11905	50589511
Cardio-respiratory arrest	45.45	34.87	35	3673	53857	50547559
Overdose	44.30	34.87	45	3663	99682	50501734
Suicide attempt	40.16	34.87	32	3676	51700	50549716
Amenorrhoea	39.90	34.87	17	3691	8467	50592949
Asphyxia	39.88	34.87	15	3693	5412	50596004
Newborn persistent pulmonary hypertension	38.21	34.87	7	3701	143	50601273
Akathisia	37.09	34.87	16	3692	8213	50593203
Anterograde amnesia	35.10	34.87	8	3700	494	50600922

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	290.06	34.31	147	5871	39303	29529206
Therapeutic product effect variable	259.36	34.31	63	5955	1814	29566695
Antipsychotic drug level below therapeutic	256.21	34.31	63	5955	1911	29566598
Disinhibition	243.61	34.31	64	5954	2543	29565966
Akathisia	239.02	34.31	78	5940	6664	29561845
Obsessive-compulsive disorder	229.39	34.31	69	5949	4507	29564002
Euphoric mood	200.48	34.31	63	5955	4762	29563747
Increased appetite	186.33	34.31	63	5955	6001	29562508
Neuroleptic malignant syndrome	160.17	34.31	74	5944	16074	29552435
Suicide attempt	130.38	34.31	83	5935	34027	29534482
Hepatocellular injury	129.61	34.31	70	5948	21173	29547336
Extrapyramidal disorder	121.16	34.31	54	5964	10777	29557732
Wrong patient received product	112.54	34.31	34	5984	2248	29566261
Rhabdomyolysis	105.48	34.31	92	5926	60716	29507793
Poisoning deliberate	102.70	34.31	40	5978	5691	29562818
Therapeutic product effect incomplete	101.25	34.31	75	5943	39230	29529279
Miosis	99.50	34.31	43	5975	7966	29560543
Dyslipidaemia	86.79	34.31	36	5982	6025	29562484
Obesity	81.82	34.31	40	5978	9823	29558686
Leukopenia	77.07	34.31	74	5944	55129	29513380
Leukaemia	76.88	34.31	29	5989	3781	29564728
Prescribed overdose	74.38	34.31	36	5982	8647	29559862
Product use in unapproved indication	72.96	34.31	89	5929	86786	29481723
Hypothermia	69.31	34.31	35	5983	9204	29559305
Somnolence	68.96	34.31	90	5928	93865	29474644
Toxicity to various agents	65.14	34.31	122	5896	173539	29394970
Weight increased	63.46	34.31	78	5940	76589	29491920
Colitis ischaemic	61.80	34.31	28	5990	5795	29562714
Hyperleukocytosis	58.22	34.31	19	5999	1616	29566893
Faecaloma	53.61	34.31	23	5995	4179	29564330
Subileus	51.42	34.31	20	5998	2830	29565679
Pneumonia aspiration	50.75	34.31	49	5969	36688	29531821
Fatigue	46.98	34.31	5	6013	316816	29251693
Bradypnoea	44.06	34.31	17	6001	2354	29566155
Blood creatine phosphokinase increased	43.06	34.31	47	5971	40597	29527912
Necrotising colitis	41.16	34.31	13	6005	995	29567514
Congestive cardiomyopathy	40.80	34.31	22	5996	6608	29561901
Tachycardia	37.75	34.31	59	5959	72351	29496158
Mydriasis	36.91	34.31	20	5998	6065	29562444
Electrocardiogram QT prolonged	36.90	34.31	41	5977	36096	29532413
Schizoaffective disorder	36.10	34.31	12	6006	1080	29567429
Hyperthermia	36.08	34.31	23	5995	9407	29559102
Compensatory sweating	35.35	34.31	6	6012	24	29568485

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	640.37	32.90	286	8449	87329	64402668
Poisoning deliberate	423.24	32.90	129	8606	13329	64476668
Neuroleptic malignant syndrome	366.97	32.90	135	8600	24861	64465136
Extrapyramidal disorder	277.31	32.90	103	8632	19449	64470548
Hepatocellular injury	268.03	32.90	128	8607	45107	64444890
Somnolence	186.58	32.90	180	8555	203465	64286532
Rhabdomyolysis	172.13	32.90	123	8612	91603	64398394
Miosis	156.02	32.90	61	8674	13205	64476792
Pneumonia aspiration	131.11	32.90	88	8647	59183	64430814
Hypothermia	129.19	32.90	60	8675	19796	64470201
Intestinal obstruction	113.18	32.90	67	8668	36219	64453778
Faecaloma	111.80	32.90	44	8691	9684	64480313
Akathisia	107.99	32.90	45	8690	11465	64478532
Wrong patient received product	105.21	32.90	33	8702	3729	64486268
Cholestasis	90.60	32.90	63	8672	44809	64445188
Catatonia	89.43	32.90	35	8700	7585	64482412
Tachycardia	88.44	32.90	105	8630	149474	64340523
Hyperthermia	85.90	32.90	42	8693	15508	64474489
Subileus	84.59	32.90	30	8705	4947	64485050
Toxicity to various agents	82.13	32.90	163	8572	363350	64126647
Altered state of consciousness	78.35	32.90	54	8681	37848	64452149
Oculogyric crisis	78.28	32.90	24	8711	2514	64487483
Blood creatine phosphokinase increased	71.54	32.90	61	8674	58497	64431500
Necrotising colitis	71.20	32.90	18	8717	926	64489071
Fatigue	71.10	32.90	9	8726	748721	63741276
Asphyxia	68.77	32.90	31	8704	9535	64480462
Cardio-respiratory arrest	68.13	32.90	75	8660	98318	64391679
Bladder dilatation	67.83	32.90	20	8715	1834	64488163
Suicide attempt	67.09	32.90	64	8671	70943	64419054
Hyperleukocytosis	65.94	32.90	20	8715	2020	64487977
Benzodiazepine drug level increased	59.86	32.90	12	8723	211	64489786
Bradypnoea	58.09	32.90	23	8712	5136	64484861
Antipsychotic drug level below therapeutic	55.98	32.90	15	8720	970	64489027
Galactorrhoea	53.18	32.90	19	8716	3200	64486797
Distal intestinal obstruction syndrome	52.27	32.90	13	8722	625	64489372
Faecal vomiting	50.74	32.90	14	8721	1011	64488986
Colitis ischaemic	50.44	32.90	28	8707	13386	64476611
Respiratory acidosis	49.62	32.90	25	8710	9830	64480167
Electrocardiogram QT prolonged	48.92	32.90	57	8678	79391	64410606
Therapeutic product effect variable	48.39	32.90	15	8720	1629	64488368
Disinhibition	47.74	32.90	16	8719	2227	64487770
Pain	47.13	32.90	9	8726	553502	63936495
Confusional state	47.12	32.90	107	8628	261037	64228960
Housebound	45.86	32.90	11	8724	454	64489543
Agitation	45.63	32.90	58	8677	88309	64401688
Congestive cardiomyopathy	45.61	32.90	24	8711	10320	64479677
Brain death	45.57	32.90	19	8716	4842	64485155
Dystonia	44.05	32.90	29	8706	18836	64471161
Product use in unapproved indication	41.91	32.90	81	8654	176537	64313460
Intentional overdose	41.72	32.90	56	8679	89888	64400109
Dyspnoea	40.04	32.90	24	8711	718650	63771347
Antipsychotic drug level above therapeutic	38.52	32.90	13	8722	1848	64488149
Hyperprolactinaemia	38.48	32.90	16	8719	4049	64485948
Psychotic disorder	38.14	32.90	34	8701	34544	64455453
Intestinal ischaemia	37.75	32.90	22	8713	11527	64478470
Urinary retention	36.63	32.90	39	8696	49162	64440835
Diabetic hyperosmolar coma	36.46	32.90	10	8725	706	64489291
Camptocormia	35.43	32.90	9	8726	472	64489525
Compensatory sweating	34.61	32.90	6	8729	45	64489952
Choking	34.25	32.90	20	8715	10518	64479479
Euphoric mood	34.00	32.90	17	8718	6574	64483423
Arthralgia	33.99	32.90	9	8726	442251	64047746
Intestinal pseudo-obstruction	33.77	32.90	12	8723	1988	64488009
Psychotic symptom	32.99	32.90	12	8723	2126	64487871

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N05AH01	NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Diazepines, oxazepines, thiazepines and oxepines
MeSH PA	D014150	Antipsychotic Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D002492	Central Nervous System Depressants
MeSH PA	D015259	Dopamine Agents
MeSH PA	D018492	Dopamine Antagonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D011619	Psychotropic Drugs
MeSH PA	D014149	Tranquilizing Agents
CHEBI has role	CHEBI:35476	neuroleptics
CHEBI has role	CHEBI:48561	dopaminergic antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Bipolar disorder	indication	13746004	DOID:3312
Schizophrenia	indication	58214004	DOID:5419
Alcoholism	contraindication	7200002
Neuroleptic malignant syndrome	contraindication	15244003	DOID:14464
Senile dementia	contraindication	15662003
Glaucoma	contraindication	23986001	DOID:1686
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Tardive dyskinesia	contraindication	102449007
Seizure disorder	contraindication	128613002
Hyperprolactinemia	contraindication	237662005	DOID:12700
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Coma	contraindication	371632003
Carcinoma of female breast	contraindication	447782002
Pigmentary Retinopathy	contraindication
Drug Induced CNS Depression	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.59	Basic
pKa2	3.24	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
D(2) dopamine receptor	GPCR	P14416	DRD2_HUMAN	ANTAGONIST	Ki	7.68	CHEMBL	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	ANTAGONIST	Ki	8.62	CHEMBL	CHEMBL
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.82	PDSP
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.24	PDSP
5-hydroxytryptamine receptor 1A	GPCR	P08908	5HT1A_HUMAN		Ki	5.61	PDSP
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	ANTAGONIST	Ki	8	IUPHAR
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	7.82	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN		Ki	7.51	PDSP
Alpha-2B adrenergic receptor	GPCR	P18089	ADA2B_HUMAN		Ki	6.97	PDSP
D(3) dopamine receptor	GPCR	P35462	DRD3_HUMAN	ANTAGONIST	IC50	7.66	CHEMBL
D(1B) dopamine receptor	GPCR	P21918	DRD5_HUMAN		Ki	7.13	PDSP
Histamine H1 receptor	GPCR	P35367	HRH1_HUMAN	ANTAGONIST	Ki	8.20	IUPHAR
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN		Ki	6.68	PDSP
Histamine H4 receptor	GPCR	Q9H3N8	HRH4_HUMAN		Ki	5.30	PDSP
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN		IC50	5.26	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		Ki	6.38	PDSP
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		Ki	6.91	PDSP
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		Ki	6.09	PDSP
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		Ki	6.83	PDSP
5-hydroxytryptamine receptor 1B	GPCR	P28222	5HT1B_HUMAN		Ki	6.41	PDSP
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	7.10	PDSP
D(4) dopamine receptor	GPCR	P21917	DRD4_HUMAN	ANTAGONIST	Ki	8.31	CHEMBL
5-hydroxytryptamine receptor 3A	Ion channel	P46098	5HT3A_HUMAN		Ki	6.72	PDSP
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN		Ki	7.28	PDSP
5-hydroxytryptamine receptor 5A	GPCR	P47898	5HT5A_HUMAN		Ki	6.11	PDSP
5-hydroxytryptamine receptor 1E	GPCR	P28566	5HT1E_HUMAN		Ki	5.85	PDSP
Potassium channel subfamily K member 2	Ion channel	O95069	KCNK2_HUMAN		IC50	4.70	CHEMBL
Potassium channel subfamily T member 1	Ion channel	Q5JUK3	KCNT1_HUMAN	ACTIVATOR	EC50	5.36	IUPHAR
5-hydroxytryptamine receptor 1D	GPCR	P28221	5HT1D_HUMAN		Ki	5.46	PDSP
D(1A) dopamine receptor	GPCR	P21728	DRD1_HUMAN		Ki	7.27	PDSP
D(2) dopamine receptor	GPCR		DRD2_RAT		Ki	7.68	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR		5HT2A_RAT		IC50	8.22	CHEMBL
5-hydroxytryptamine receptor 7	GPCR		5HT7R_RAT		Ki	7.37	CHEMBL
5-hydroxytryptamine receptor 2C	GPCR		5HT2C_RAT		IC50	6	CHEMBL
Histamine H1 receptor	GPCR		HRH1_RAT		IC50	6	CHEMBL
5-hydroxytryptamine receptor 6	GPCR		5HT6R_RAT	ANTAGONIST	Ki	7.80	IUPHAR
Adrenergic receptor alpha-1	GPCR		ADA1B_RAT ADA1D_RAT ADA1A_RAT		IC50	7.74	CHEMBL

External reference:

ID	Source
4019805	VUID
N0000147894	NUI
D00794	KEGG_DRUG
27833-64-3	SECONDARY_CAS_RN
54810-23-0	SECONDARY_CAS_RN
4017917	VANDF
4017918	VANDF
4019805	VANDF
C0024056	UMLSCUI
CHEBI:50841	CHEBI
CHEMBL831	ChEMBL_ID
CHEMBL1201155	ChEMBL_ID
DB00408	DRUGBANK_ID
D008152	MESH_DESCRIPTOR_UI
3964	PUBCHEM_CID
205	IUPHAR_LIGAND_ID
2610	INN_ID
LER583670J	UNII
1364415	RXNORM
1308	MMSL
1346	MMSL
196711	MMSL
29026	MMSL
4999	MMSL
5000	MMSL
d00897	MMSL
001522	NDDF
001523	NDDF
001524	NDDF
1971003	SNOMEDCT_US
30745005	SNOMEDCT_US
372789006	SNOMEDCT_US
59270007	SNOMEDCT_US
CHEMBL1201060	ChEMBL_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1394	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1395	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1396	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0527-1397	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0369	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0370	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0371	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	0591-0372	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-585	TABLET	5 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-586	TABLET	10 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-587	TABLET	25 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	10135-588	TABLET	50 mg	ORAL	ANDA	19 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	17856-1397	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-436	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-437	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-438	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	35573-439	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4701	CAPSULE	10 mg	ORAL	ANDA	21 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4701	CAPSULE	10 mg	ORAL	ANDA	21 sections
Adasuve	HUMAN PRESCRIPTION DRUG LABEL	1	51097-001	AEROSOL, POWDER	10 mg	RESPIRATORY (INHALATION)	NDA	31 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-890	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-891	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-892	CAPSULE	25 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	64850-893	CAPSULE	50 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	68151-2875	CAPSULE	5 mg	ORAL	ANDA	18 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0283	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0283	CAPSULE	10 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0346	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0346	CAPSULE	5 mg	ORAL	ANDA	20 sections
Loxapine	HUMAN PRESCRIPTION DRUG LABEL	1	70518-0347	CAPSULE	25 mg	ORAL	ANDA	20 sections